BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

Active, not recruiting

Conditions: Gastric Cancer
Gastroesophageal Junction Cancer

Interventions: Drug: Nivolumab

First Posted Date: 2024-06-11

Last Posted Date: 2024-06-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 260

Registration Number: NCT06452329

Locations: 🇨🇳
Tianjin Happy Life Technology Co., Ltd, Shanghai, China

Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments

Not yet recruiting

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Approved Non-small Cell Lung Cancer (NSCLC) therapies

First Posted Date: 2024-06-07

Last Posted Date: 2024-06-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 55

Registration Number: NCT06448793

Locations: 🇬🇧
Evidera, London, United Kingdom

Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

Phase 1

Recruiting

Conditions: Hepatic Impairment
Healthy Participants

Interventions: Drug: BMS-986278

First Posted Date: 2024-05-22

Last Posted Date: 2024-12-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 48

Registration Number: NCT06425198

Locations: 🇺🇸
Local Institution - 0001, Miami Lakes, Florida, United States
🇺🇸
Local Institution - 0003, Orlando, Florida, United States
🇺🇸
Elixia, Tampa, Florida, United States

and more 1 locations

Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy

Recruiting

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: Systemic therapy

First Posted Date: 2024-05-20

Last Posted Date: 2024-10-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 300

Registration Number: NCT06422247

Locations: 🇯🇵
Mebix, Inc, Minato-ku, Tokyo, Japan

Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France

Recruiting

Conditions: Urothelial Carcinoma

Interventions: Drug: nivolumab

First Posted Date: 2024-05-20

Last Posted Date: 2024-08-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 300

Registration Number: NCT06421311

Locations: 🇫🇷
KAPPA SANTE Institution, Paris, France
🇫🇷
ICANS Institut de Cancérologie Strasbourg Europe, Strasbourg, France

Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Drug: BMS-986497

First Posted Date: 2024-05-17

Last Posted Date: 2024-11-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 35

Registration Number: NCT06419634

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
Local Institution - 0010, Chicago, Illinois, United States

and more 8 locations

A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis

Phase 4

Recruiting

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: BMS-986374

First Posted Date: 2024-05-02

Last Posted Date: 2024-08-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 84

Registration Number: NCT06396039

Locations: 🇨🇳
Local Institution - 0016, Shanghai, Shanghai, China
🇨🇳
The First People's Hospital of Yunnan Province, Kunming, Yunnan, China
🇨🇳
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

and more 25 locations

A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)

Recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: Apremilast
Drug: Deucravacitinib

First Posted Date: 2024-04-25

Last Posted Date: 2024-04-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 600

Registration Number: NCT06382987

Locations: 🇯🇵
Mebix. Inc., Minato-ku, Tokyo, Japan
🇯🇵
Fukuoka University Hospital, Fukuoka, Japan

COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Active, not recruiting

Conditions: Hypertrophic Cardiomyopathy (HCM)

Interventions: Drug: Approved Hypertrophic Cardiomyopathy drug treatments
Drug: Mavacamten

First Posted Date: 2024-04-18

Last Posted Date: 2024-04-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 500

Registration Number: NCT06372457

Locations: 🇺🇸
IQVIA, Durham, North Carolina, United States

Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada

Completed

Conditions: Upper Gastrointestinal Cancer

Interventions: Drug: Nivolumab

First Posted Date: 2024-04-12

Last Posted Date: 2024-04-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 250

Registration Number: NCT06361563

Locations: 🇨🇦
Bayshore Specialty Rx Ltd., Mississauga, Ontario, Canada

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy